


5th – 6th June 2025 Antwerp, Belgium

Commemorating 10 years of achievements of the HPV Prevention and Control Board



Focused Topic Technical Meeting

Background




Routine Universal HPV Vaccination

Gender Target:

Inclusion of male cohorts as secondary targets (understanding that the highest HPV-related burden of disease is on the cervix, thus making female cohorts historically the primary priority target)

Age Target:

Understanding that current HPV vaccine products offer prophylactic protection, thus, vaccination before exposure to the virus is desired for highest efficacy. Vaccination of male cohorts between 9 – 14 years of age.



Anal Cancer Screening


HPV disease is not limited to the cervix but also to other mucosal tissues like the vulva, vagina, penis, anal and also oropharyngeal. For the screening component of the technical meeting, we will focus on the anal cancer screening continuum and impact (both affecting males and females)



From Gender-Neutral to Routine Universal

Terminology Discussion


During previous discussions among **scientific advisers of the HPV Prevention and Control Board**, a shift in the terminology used to describe the expansion of target groups for HPV vaccination, from "gender-neutral" to "routine universal" HPV vaccination, was proposed:



- ➤ Universal proposes a more comprehensive framing: **HUMAN** papillomavirus infects all human beings indistinctive of gender.
- The term "routine universal" helps to move away from the association of **female-exclusive burden** of HPV as a disease primarily affecting women and instead positions it as a universal infection with consequences for all.
- ➤ "Routine" refers to the systematic delivery of the vaccine to specific age cohorts identified as having the greatest benefit, aligning with established immunization practices.
- ➤ Parallel vaccination programs, such as Hepatitis B, shifted from a risk-group approach to a "universal" childhood vaccination, without gender-specific language in their delivery terms.
- Adopting "routine universal" for HPV vaccination brings consistency with these precedents while better reflecting the **inclusive nature of the program**.



Technical Meeting Preparation



Literature Review



Literature Review







Anal Cancer Screening

Anal Cancer[Mesh] Anal Carcinoma[mp] Anal
Neoplasms[Mesh] Anal Intraepithelial
Neoplasia [Mesh] AIN [mp]

Early Cancer
Detection[Mesh] screening
guidelines[mp] screening
recommendations
[mp] - prevention
strategies[mp] early
detection[mp]

/ 10 **** years

104

Papillomaviridae [Mesh] - HPV[mp] - Human papillomavirus[mp]

26 were selected + 10 added manually

HPV Vaccination in Males

Safety[Mesh] - Adverse
Effects[Mesh] - Adverse
event[mp] - Side effect[mp] Efficacy[mp] Effectiveness[mp] - Vaccine
effectiveness[mp] Impact[mp] - Population
impact[mp] - Program
evaluation[Mesh] Implementation[mp] Vaccine coverage[mp] Uptake[mp] - Vaccination
acceptance[mp] Hesitancy[mp]


Papillomavirus
Vaccines[Mesh] - HPV
Vaccin*[mp] - Human
papillomavirus
Vaccin*[mp]

10
years

Male[Mesh] Men[mp] Boy*[mp] - Young
men[mp] - Young
adult[Mesh]

52 were selected + 16 added manually

Technical Meeting Preparation



Literature Review Advisers & Scientific
Organizing Committee
Meetings



Advisers & Scientific Organizing Committee Meeting

Technical Meeting Preparation





Advisor Meeting 12th of February, 2025 Istanbul, Turkey




Advisor Meeting 4th of December, 2024 online



Scientific Organising
Committee 7th of March,
2025
online

Technical Meeting Preparation




Literature Review Advisers & Scientific
Organizing Committee
Meetings

One-on-one contact with experts on the field and speakers



Technical Meeting Preparation




Literature Review Advisers & Scientific
Organizing Committee
Meetings

One-on-one contact with experts on the field and speakers

Focused topic meeting agenda and objectives



Routine Universal HPV Vaccination and the Role of Anal Screening



- Review the epidemiological data and scope of **HPV-related morbidity in females and males** and their respective anatomical site burden.
- Discuss available evidence in HPV natural history in males.
- Examine the extent of impact by which male cohorts' vaccination can reduce HPV-related disease both directly and indirectly (through transmission and herd protection).




Routine Universal HPV Vaccination and the Role of Anal Screening

- Present up-to-date clinical and real-world data on the safety profile and immunogenicity of HPV vaccines in male cohorts.
- Discuss vaccine effectiveness data specific to preventing HPV-related diseases in male cohorts.
- Examine current evidence on anal canal screening tools to prevent, control and manage HPV-driven anal cancer.





Routine Universal HPV Vaccination and the Role of Anal Screening




OF ROUTINE UNIVERSAL HPV VACCINE

- Asses the HPV vaccine supply forecasting leading to informed decision making
- Present real-world examples from various countries to illustrate the **considerations** of this policy in their respective contexts.
- Assess the implementation considerations and cost-effectiveness analyses that inform stakeholders on routine universal HPV vaccination policies.
- Explore facilitators and barriers to achieving equitable coverage and program resilience.
- Draw parallels to historical shifts in other vaccination programs and how these precedents can guide HPV vaccination strategies.



Routine Universal HPV Vaccination and the Role of Anal Screening

- Review emerging and established guidelines for anal canal screening, including recommendations (target, sample collection, laboratory testing methodologies, treatment, triage) to ensure comprehensive care and high-quality data.
- Discuss how non-cervical screening (anal cancer screening) initiatives could be integrated to better capture the impact of vaccinating male cohorts.
- Understand and discuss the status and steps towards implementation, considering resource allocation, workforce training, infrastructure needs, and strategies to promote equitable access.



Anal Cancer Screen ing and Assessing Impact



Meeting Agenda: Day 1

Routine Universal HPV Vaccination and the Role of Anal Screening



HPV-related disease: where are we now?

9:30 - 10:15

Session 4

HPV Vaccination in male cohorts: Safety, efficacy and impact

13:30 - 14:35

Session 6

From data to policy of Routine Universal Vaccination.

15:50 -17:15

Coffee Break 10:15 – 10:35

Lunch Break 12:30 – 1:30 **Coffee Break 15:30 – 15:50**

Session 1

Welcome and Introduction

9:00 - 9:30

Session 3

Current Landscape of Anal Cancer Screening

10:35 -12:30

Session 5

Panel Discussion on HPV Vaccine Global Supply

14:35 -15:30

Session 7

Emerging Topic
Discussion – Poll
Requesting Input

17:15 - 17:30





10 YEARS RECEPTION

Join us at the City Hall of Antwerp to cheers to 10 years of achievements of these scientific group of experts

*A transport service has been arranged to bring guest to and from the city hall of Antwerp leaving at 18:00



10 YEAR RECEPTION

in commemoration of a decade of achievements. Including 17 scientific meetings and a significant impact on fostering evidence-based, thought-provoking discussions, we are delighted to delebrate ten years of our HPV Board activities. With the continued support of our esteemed board advisors, we look forward to both honouring our trajectory and embracing the promising future ahead.

Thursday

5

At 06:45 PM

2029

Antwerp City Hall, Belgium

*Floase note a housten service has been a ranged from the most he venue to the reception.

Meeting Agenda: Day 2

Routine Universal HPV Vaccination and the Role of Anal Screening

